Biota Announces Shareholder Approval of Merger With Nabi

Biota Announces Shareholder Approval of Merger With Nabi
MELBOURNE, AUSTRALIA -- (Marketwire) -- 10/23/12 --  Biota Holdings
Limited (ASX: BTA) today announced shareholder approval of a merger
with Nabi Biopharmaceuticals to create the combined company, Biota
Pharmaceuticals. The merger was supported by 94% of shares and 82% of
holders at an October 23, 2012 meeting. 
Biota's merger with Nabi is being undertaken by way of a Scheme of
Arrangement (Scheme) and is subject to final approval of the Supreme
Court of Victoria later this week. Following final approval, Biota
shareholders will hold approximately 83% of the NASDAQ-listed, Biota
"This agreement is a significant step for Biota and the progress of
our Company," said Dr. James Fox, Chairman of Biota. "Today's vote by
Biota shareholders follows the support of Nabi shareholders, who
voted in favour of the merger last night. The merger is an important
step to help us to unlock value from our portfolio, and in particular
from our second generation influenza anti-viral, laninamivir." 
Biota will apply to the Supreme Court of Victoria for approval of the
Scheme at a hearing scheduled for October 26, 2012. The Board will
make a further announcement to the ASX after the Court has considered
the matter. If the Court approves the Scheme, Biota proposes to lodge
the Court orders with the Australian Securities and Investments
Commission on October 30, 2012 and the Scheme will become effective
on that date. Biota shares will then cease trading on the ASX at
close of trade that day. 
Biota shareholders will be issued with shares in the merged group,
Biota Pharmaceuticals, Inc. beginning on November 9, 2012. The merged
group will commence trading with NASDAQ's opening on November 9 at
9:00AM EST. It is recommended that shareholders wait to receive
formal advice on their holdings in Biota Pharmaceuticals Inc., before
undertaking any dealings in those holdings. 
About Biota 
Biota is a leading anti-infective drug development company based in
Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza. Biota research breakthroughs include a
series of candidate drugs aimed at treatment of respiratory syncytial
virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has
a well advanced program for human rhinovirus (HRV) infection with a
completed Phase IIb study in asthmatic subjects. 
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza antivirals, of which the lead product lnavir(R),
is marketed in Japan. Biota holds a contract from the US Office of
Biomedical Advanced Research and Development Authority (BARDA) for
the advanced development of laninamivir in the USA.  
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of
 Inavir(R) is registered to Daiichi Sankyo. 
Further information 
Investor/Analyst Enquiries
Biota Holdings Limited 
Peter Cook 
T: +61 3 9915 3720
Damian Lismore 
T: +61 3 9915 3721 
Shareholder Enquiries
Biota Shareholder Information Line
T: 1300 306 230 (within Australia)
T: +61 2 8280 7169 (International)
Between 8:30am and 7:30pm
(Melbourne time) 
Media Enquiries
Nerida Mossop
Hinton & Associates
T: +61 3 9600 1979
M: +61 437 361 433 
Felicity Williams
Hinton & Associates
T: +61 3 9600 1979
M: +61 416 770 012 
US Enquiries
Hershel Berry
Blueprint Life Science Group
M: +1 415 505 3749 
Press spacebar to pause and continue. Press esc to stop.